1. Autologous Multi-lineage Potential Cell, AMPC

Autologous Multi-lineage Potential Cell, that is AMPC self-multipotent differentiation cell, which is derived from autologous blood cells. With the patent of Australia ASCT blood stem cell induction and culture, cultured in a special microenvironment for 4 to 5 days, it can effectively induce blood cells into stem cell with the ability of multi-lineage differentiation potential.

The experiments demonstrate that AMPC can differentiate in specific growth conditions.

3. AMPC is a non-genetically regulated cell product. It is cultured without any animal serum, growth factors and antibiotics and is produced in a closed-system operating system. The safety of the process products is reviewed and approved by the Australian Health Unit Therapeutic Goods Administration (TGA) and can be legally provided for use by medical units.

4. ASCT was founded in 2011. It is located in Brisbane Science Park, Australia. Since January 2013, it has carried out hundreds of cases. At present, ASCT has cooperated with the famous Queensland Medical Center in the first phase of clinical trial on myocardial damage. In the future, it is planned to conduct joint research with various medical teams in many pilot projects around the world and devote itself to the development of direct and adjuvant therapies for disease treatment. Expect to contribute to the human health medical environment.

5. ASCT is audited and supervised by the Australian Health Authority, TGA, NATA, ISO International Standards Organization and VERO Medical Insurance Company.

6. Course of treatment

Travel suggestions: 8 days and 7 nights